This technology is a set of ibogaine analogues with distinct pharmacological mechanisms from the naturally occurring alkaloid ibogaine.
The naturally occurring, psychoactive alkaloid ibogaine has demonstrated anti-addictive properties in various animal models, indicating its potential as a treatment for patients with substance use disorders. However, the naturally occurring alkaloid ibogaine has also been found to have negative effects, including cardiac toxicity that can lead to death.
These ibogaine analogues have simple chemical structures that enable them to target specific receptors via a unique pharmacological mechanism. The analogues are benzofurano-tetrahydroazepines and have been shown to have better hERG/cardiac profiles compared to both naturally occurring alkaloid ibogaine and previously developed analogues. This technology may be useful in developing safe pharmaceutical treatments for substance use disorders and other psychiatric disorders.
This technology has been tested for function and side effects in vitro and in vivo.
Patent Pending
IR CU21150
Licensing Contact: Beth Kauderer